课题基金 / 基金详情

Serotonin 5-HT2A receptor inhibition of TNF-alpha pathways and atherosclerosis

Serotonin 5-HT2A receptor inhibition of TNF-alpha pathways and atherosclerosis
血清素 5-HT2A 受体抑制 TNF-α 通路和动脉粥样硬化
批准号:
7990321
负责人:
CHARLES D NICHOLS
金额:
$21.3万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-15 至 2012-06-30

项目摘要

项目成果

CHARLES D NICHOLS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The overall goals of this project are to elucidate the molecular mechanisms underlying our recent discovery that serotonin 5-HT2A receptor activation super-potently inhibits TNFa-mediated inflammatory pathways, and to translate our findings to an animal model as a potential novel therapeutic approach to treat and/or prevent diseases like atherosclerosis that involve TNFa-mediated inflammation. TNF- a-mediated inflammatory pathways have been strongly implicated in a number of diseases including atherosclerosis, rheumatoid arthritis, psoriasis, type II diabetes, irritable bowel syndrome and Crohn's disease, and septicemia. Significantly, TNF-a and other cytokine induced inflammatory pathways also have been linked to psychiatric conditions such as depression and bipolar disorder, as well as schizophrenia, and neurodegenerative diseases. As such, inhibitors of TNF-a pro-inflammatory pathways represent potential therapeutics for each of these conditions. Currently, the only available therapeutic inhibitors of TNF-a pathways are monoclonal antibodies against TNF-a (infliximab and adalimumab) and soluble TNF-a receptor (etanercept), and the development of small molecules for this purpose is highly desirable. We have recently discovered that activation of 5-HT2A receptors in cardiovascular tissues including primary aortic smooth muscle, aortic endothelial, and macrophage cells by (R)-DOI, and likely additional 5-HT2A receptor agonists, represents a novel, and extraordinarily potent, therapeutic avenue to develop for the treatment of diseases and disorders involving TNF-a-mediated inflammation. Significantly, pro-inflammatory marker blockade occurs with IC50 drug levels of 10-20 picomolar. With the exception of a few natural toxins no current drugs or small molecule therapeutics demonstrate a comparable potency for any physiological effect. The experiments described in this proposal will elucidate the molecular signaling pathways linking activation of 5-HT2A receptors to inhibition of TNF- a-mediated pro-inflammatory process using molecular and biochemical approaches in primary cell culture experiments. Importantly, we will also perform translational studies in rodents to explore the anti-inflammatory effects of (R)-DOI in vivo. Results from these studies may lead to potential therapeutic strategies to not only prevent, but also treat existing pathological conditions like atherosclerosis via 5-HT2A receptor stimulation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Drosophila to elucidate serotonin's role in stimulant drug abuse
  • 批准号:
    9312276
  • 项目类别:
  • 资助金额:
    $18.25万
  • 财政年份:
    2016
  • 负责人:
    CHARLES D NICHOLS
  • 依托单位:
Serotonin 5-HT2A receptor inhibition of TNF-alpha pathways and atherosclerosis
  • 批准号:
    8109955
  • 项目类别:
  • 资助金额:
    $17.75万
  • 财政年份:
    2010
  • 负责人:
    CHARLES D NICHOLS
  • 依托单位:
Combining mammalian and Drosophila systems to study neuropsychiatric disorders
  • 批准号:
    7663595
  • 项目类别:
  • 资助金额:
    $35.16万
  • 财政年份:
    2009
  • 负责人:
    CHARLES D NICHOLS
  • 依托单位:
Combining mammalian and Drosophila systems to study neuropsychiatric disorders
  • 批准号:
    7888385
  • 项目类别:
  • 资助金额:
    $35.15万
  • 财政年份:
    2009
  • 负责人:
    CHARLES D NICHOLS
  • 依托单位:
海外基金